Capricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development
27 févr. 2015 09h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 27, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock
04 févr. 2015 09h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET
21 janv. 2015 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases...
Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure
12 janv. 2015 12h32 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces $10 Million Private Placement of Common Stock
12 janv. 2015 09h26 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray's 26th Annual Healthcare Conference
02 déc. 2014 07h45 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
18 nov. 2014 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy
18 nov. 2014 07h45 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights
12 nov. 2014 08h30 HE
|
Capricor Therapeutics, Inc.
Announced Plans for Cenderitide Clinical Program and Clinical Program for Duchenne Muscular Dystrophy
Conference Call Scheduled for Wednesday, November 12, 2014 (4:30 p.m. EST)
LOS ANGELES,...
Capricor Therapeutics to Hold Duchenne Muscular Dystrophy Data Presentation Call on November 18, 2014 at 9:30 a.m. ET
07 nov. 2014 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...